查詢結果分析
相關文獻
- 非小細胞肺癌免疫療法藥物簡介
- Pembrolizumab於非小細胞肺癌之療效
- PD-L1抑制劑--Atezolizumab用於晚期轉移性NSCLC
- A Novel Experience of Nivolumab-Associated Toxic Epidermal Necrolysis in a Patient with Metastatic Non-Small Cell Lung Cancer in Taiwan--A Case Report
- 非小細胞肺癌術前輔助性化學治療的經驗
- Molecular Mechanisms of Allergen-Specific Immunotherapy for Atopic Diseases
- The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer
- Differential Display of mRNA in Human Lung Tissue and in Non-Small Cell Lung Cancer: A Preliminary Report
- 非小細胞肺癌的治療
- 肝癌之非外科治療
頁籤選單縮合
題名 | 非小細胞肺癌免疫療法藥物簡介=Introduction of Immune Therapy in Non-small Cell Lung Cancer |
---|---|
作者 | 陳弘益; | 書刊名 | 藥學雜誌 |
卷期 | 35:1=138 2019.03[民108.03] |
頁次 | 頁27-31 |
分類號 | 418.31 |
關鍵詞 | 非小細胞肺癌; 免疫療法; Immunotherapy; Nivolumab; Pembrolizumab; Atezolizumab; |
語文 | 中文(Chinese) |
中文摘要 | 衛福部國健署於105年4月公布102年癌症發生統計報告,肺癌是十大癌症死因順位 排行第一位,新增個案11,751位,人數在所有癌症中排名第二,肺癌中約有85%屬於 非小細胞肺癌 (non-small cell lung cancer NSCLC)。NSCLC 病人約有2-7%會有致癌基 因 ALK (anaplastic lymphoma kinase, 間變性淋巴瘤激酶) 基因轉位突變 (translocation), NSCLC 亞洲病人約有50%有表皮生長因子接受器 (Epidermal Growth Factor Receptor, EGFR) 突變,若是 EGFR 無突變、ALK 檢測也呈現陰性的 NSCLC 病人,經過第 一線含鉑類化療藥品治療後惡化者,可以採用免疫療法藥品,例如 nivolumab、 pembrolizumab 和 atezolizumab。Pembrolizumab 在腫瘤表現 PD-L1 (tumor proportion score ≥ 50%) 且 EFGR、ALK、ROS-1陰性或未知,可做為第一線治療,是一大亮點。 |
英文摘要 | In April 2016, health promotion administration, ministry of health and welfare announced cancer statistics of 2013. There were 11,751 new lung cancer cases in Taiwan and ranked second after colorectal cancer. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases. Anaplastic lymphoma kinase (ALK) fusion oncogene positive NSCLC account for 2-7% of all advanced NSCLC. Progressed patients who have neither EGFR mutation nor ALK rearrangement are candidates for immune therapy after first line platinum based chemotherapy, such as nivolumab, pembrolizumab and atezolizumab. The spotlight is on pembrolizumab. Patients with high PD-L1 expression (tumor proportion score ≥ 50%) as well as unknown or negative EFGR, ALK or ROS-1 status are candidates for first line pembrolizumab therapy. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。